Mayo Clinic Cancer Center

Oncology Precision Medicine Market, 2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 26, 2024
Pharmaceutical, Health, Oncology, Molecule, USD, Mortality, Radiation, Volunteering, Administration, Breast cancer, Cancer, Lung cancer, World Health Organization, Hub, Risk, Immunotherapy, Research, Genetic testing, Obesity, Disease, DNA, Therapy, Oncogene, Patient, Gastrointestinal cancer, Bone marrow, MD Anderson Cancer Center, Clinical trial, Medicine, Viral, Type, Interest, Mayo Clinic Cancer Center, Growth, Prevalence, Medical imaging

The growth in the oncology precision medicine market size over the next decade is likely to be the result of an anticipated increase in patient population and rise in the demand for personalized medicine in oncology for precision cancer care.

Key Points: 
  • The growth in the oncology precision medicine market size over the next decade is likely to be the result of an anticipated increase in patient population and rise in the demand for personalized medicine in oncology for precision cancer care.
  • Regional Analysis: North America Emerged as the Hub of Oncology Precision Medicine; Europe to be the Fastest Growing Market
    In 2024, North America is anticipated to capture close to 42% market share of the overall oncology precision medicine market.
  • In recent years, demand for oncology precision medicine has witnessed a tremendous increase in North America.
  • The oncology precision medicine market report presents an in-depth analysis of various precision medicine oncology companies in this domain, across different segments, as defined below:

Cancer Nutrition Consortium Releases Cookbook to Provide Cancer Patients with Best Nutrition Possible

Retrieved on: 
Monday, January 9, 2023
Cancer, Taste, Johns Hopkins, Patient, Sidney Kimmel Comprehensive Cancer Center, Food, Research, Ohio State University, Knowledge, Mayo Clinic Cancer Center, Terminology of the Low Countries, Digestion, Ohio State University Wexner Medical Center, Radiation, Nausea, Treatment, Physician, Impact, CNC, Appetite, Sidney Kimmel, Life, Diagnosis, Dana, Collection, Dietary supplement, Pharmaceutical industry, Cooking, Cookbook

BOSTON, Jan. 9, 2023 /PRNewswire-PRWeb/ -- Food is one of the basic necessities of life.

Key Points: 
  • Cookbook is a collection of nutrition-focused recipes, based on clinical research, designed to give cancer patients the best nutrition possible while facing challenges during chemotherapy, radiation, and surgical treatments.
  • According to a 2015 study, "The Impact of Cancer Treatment on the Diets & Food Preferences of Patients Receiving Outpatient Treatment" , one of the biggest challenges for people undergoing cancer treatment is getting proper nutrition.
  • Cooking Through Treatment is produced and published by the Cancer Nutrition Consortium (CNC), a non-profit that works to promote and better understand the importance of nutrition for positive medical outcomes for patients during cancer treatment and recovery.
  • The Cancer Nutrition Consortium, Inc. is approved as a tax-exempt, not-for-profit 501(c)(3) corporation organized in the State of Florida.

Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors

Retrieved on: 
Monday, December 12, 2022
Oncology, Associate professor, Fox Chase Cancer Center, Prostate, Health, Cancer, Professor, Neoplasm, NCCN, Policy, Patient, Associate, SCM, City, Pharmacist, Wilms' tumor, Pharmacology, Fatigue, Duke Cancer Institute, University of Michigan Rogel Cancer Center, Bioethics, MPH, University, National Comprehensive Cancer Network, Dizziness, MD Anderson Cancer Center, Overalls, NETS, Education, MBA, Harborside, Report, Hematology, JD, Chair, Internal medicine, Haematopoietic system, City of Hope, Communication, Duke University Hospital, Mayo Clinic Cancer Center, UCSF, Strathcona County, Survival, Caregiver, UCSF Helen Diller Family Comprehensive Cancer Center, Life expectancy, Public policy, Medical imaging, Pharmaceutical industry, Research, Epidemiology, MD, Medicine, Hope, UAB, Doctor of Philosophy

PLYMOUTH MEETING, Pa., Dec. 12, 2022 /PRNewswire/ -- New research from cancer research and treatment organization City of Hope in the December 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that only 30% of patients with advanced neuroendocrine tumors (NETs) say their top goal for treatment is living longer. The remaining patients selected other single specific treatment goals as most important, such as maintaining the ability to do daily activities, reducing or eliminating pain, or reducing or eliminating symptoms like fatigue. 66.7% of those surveyed agreed with the statement: "I would rather live a shorter life than lose my ability to take care of myself."

Key Points: 
  • However, respondents felt their doctors were more singularly focused on extending overall survival, even if it impacted other outcomes.
  • Only 51.7% of patients perceived that they had the same treatment goals as their physician.
  • Complimentary access to " Patient-Defined Goals and Preferences Among Adults With Advanced Neuroendocrine Tumors " is available until March 10, 2023.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors

Retrieved on: 
Monday, December 12, 2022
Oncology, Associate professor, Fox Chase Cancer Center, Prostate, Health, Cancer, Professor, Neoplasm, NCCN, Policy, Patient, Associate, SCM, City, Pharmacist, Wilms' tumor, Pharmacology, Fatigue, Duke Cancer Institute, University of Michigan Rogel Cancer Center, Bioethics, MPH, University, National Comprehensive Cancer Network, Dizziness, MD Anderson Cancer Center, Overalls, NETS, Education, MBA, Harborside, Report, Hematology, JD, Chair, Internal medicine, Haematopoietic system, City of Hope, Communication, Duke University Hospital, Mayo Clinic Cancer Center, UCSF, Strathcona County, Survival, Caregiver, UCSF Helen Diller Family Comprehensive Cancer Center, Life expectancy, Public policy, Medical imaging, Pharmaceutical industry, Research, Epidemiology, MD, Medicine, Hope, UAB, Doctor of Philosophy

PLYMOUTH MEETING, Pa., Dec. 12, 2022 /PRNewswire/ -- New research from cancer research and treatment organization City of Hope in the December 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that only 30% of patients with advanced neuroendocrine tumors (NETs) say their top goal for treatment is living longer. The remaining patients selected other single specific treatment goals as most important, such as maintaining the ability to do daily activities, reducing or eliminating pain, or reducing or eliminating symptoms like fatigue. 66.7% of those surveyed agreed with the statement: "I would rather live a shorter life than lose my ability to take care of myself."

Key Points: 
  • However, respondents felt their doctors were more singularly focused on extending overall survival, even if it impacted other outcomes.
  • Only 51.7% of patients perceived that they had the same treatment goals as their physician.
  • Complimentary access to " Patient-Defined Goals and Preferences Among Adults With Advanced Neuroendocrine Tumors " is available until March 10, 2023.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

HOPA Survey Reveals Frequent Drug Shortages and Increased Risks for Medication Errors

Retrieved on: 
Friday, June 3, 2022
Vinblastine, Time, CARES Act, Mayo Clinic Cancer Center, Hotel manager, Effect, Legislation, Pharmacist, BCG, HOPA, Doctor of Pharmacy, Organization, Vincristine, Government, Student, COVID-19, National, Research, JCO, Organic acid, Pharmacy, Public health, Patient safety, Cancer, Medical imaging, Medicine

MILWAUKEE, June 3, 2022 /PRNewswire-PRWeb/ -- A survey of US oncology pharmacists recently published in JCO® Oncology Practice reports that oncology drug shortages continue to present serious barriers to providing effective cancer care. Disruptions caused by drug shortages can lead to delays in the timing of chemotherapy treatments, alterations in the dose or regimen administered, or even missed doses when alternative agents are unavailable. Read the JCO article.

Key Points: 
  • MILWAUKEE, June 3, 2022 /PRNewswire-PRWeb/ -- A survey of US oncology pharmacists recently published in JCO Oncology Practice reports that oncology drug shortages continue to present serious barriers to providing effective cancer care.
  • The National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association (HOPA) Survey investigated the impact of oncology drug shortages in a variety of practice settings in the United States.
  • Sixty-three percent of institutions reported one or more drug shortages per month, with a 34% increase in 2019 from 2018.
  • A recent HOPA Drug Shortages Issue Brief provides recommendations for collaborative efforts among drug manufacturers, healthcare professionals, patient advocacy organizations, and government agencies to help mitigate disruptions caused by oncology drug shortages.

GM-CSF Knock-out CAR-T Study Published in Peer-Reviewed Journal Leukemia

Retrieved on: 
Wednesday, April 20, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, SHIELD, Granulocyte-macrophage colony-stimulating factor, Cytokine release syndrome, GM-CSF, Adoption, Judgement, Lenzilumab, COVID-19, MBA, Twitter, Graft-versus-host disease, Gilead Sciences, Research, NHL, CMML, Toxicity, Chronic myelomonocytic leukemia, Risk, Patient, Goal, GM, Degenerative disease, Toxic shock syndrome, LinkedIn, Blood, Neurotoxicity, Mayo Clinic Cancer Center, Rheumatoid arthritis, Nasdaq, Apoptosis, RAS, SEC, Forward-looking statement, Chemokine, Safety, DLBCL, Disease, Physician, Non-Hodgkin lymphoma, CRS, Knowledge, Neuroinflammation, Synthetic biology, Vaccine, Pharmaceutical industry, Leukemia, Morris, Facebook

Treatments that can prevent ICANS and CRS while potentially improving CAR-T efficacy could address a critical unmet need.

Key Points: 
  • Treatments that can prevent ICANS and CRS while potentially improving CAR-T efficacy could address a critical unmet need.
  • The upcoming Phase 3 CAR-T study, known as SHIELD, will determine the efficacy and safety of prophylactic lenzilumab on the rates of ICANS, CRS, and CAR-T efficacy.
  • The SHIELD trial has been designed to build on the positive results from the ZUMA-19 study.
  • A study of lenzilumab is also underway for patients with chronic myelomonocytic leukemia (CMML) exhibiting RAS pathway mutations.

HOPA President Brings Expertise and Unique Perspective to Hematology/Oncology Pharmacy Practice

Retrieved on: 
Friday, April 8, 2022
Drake University, Mayo Clinic Cancer Center, Immunotherapy, Board, Doctor of Pharmacy, HOPA, Cancer, Mayo Clinic College of Medicine and Science, Pharmacist, Assistant, Hotel manager, Mayo Clinic, Military Professional Resources Inc., COVID-19, Student, Patient, Professional development, Radiation, Hospital, Medicine, Pharmacy, Research, Advocacy

MILWAUKEE, April 8, 2022 /PRNewswire-PRWeb/ -- Heidi D. Finnes, PharmD, BCOP, FHOPA became President of the Hematology/Oncology Pharmacy Association (HOPA) on April 1, 2022, at the association's annual conference in Boston, Massachusetts. Dr. Finnes previously served as an At-Large Member on the HOPA Board of Directors from 2015 to 2019 and has volunteered on and led numerous committees and task forces.

Key Points: 
  • Dr. Finnes is Senior Manager, Pharmacy Cancer Research at the Mayo Clinic Cancer Center in Rochester, Minnesota, and Assistant Professor of Pharmacy in the Mayo Clinic College of Medicine.
  • MILWAUKEE, April 8, 2022 /PRNewswire-PRWeb/ -- Heidi D. Finnes, PharmD, BCOP, FHOPA became President of the Hematology/Oncology Pharmacy Association (HOPA) on April 1, 2022, at the association's annual conference in Boston, Massachusetts.
  • She also will lead HOPA members to expand on novel opportunities to improve oncology pharmacy practice in a post-COVID-19 world.
  • About HOPA: The Hematology/Oncology Pharmacy Association (HOPA) supports hematology/oncology pharmacy professionals and promotes the role of the pharmacist in collaborative cancer care.

PANCREATIC CANCER ACTION NETWORK ADAPTIVE CLINICAL TRIAL ADDS NEW INVESTIGATIONAL TREATMENT AND ADDITIONAL SITES

Retrieved on: 
Thursday, March 24, 2022
University, Pancreatic cancer, Population, Country, Pancreatic Cancer Action Network, Research, Huntsman Cancer Institute, University of Michigan Rogel Cancer Center, JD, Mayo Clinic Cancer Center, CEO, PD-1, Adaptive clinical trial, Twitter, MBA, Physician, Precision, Instagram, LOS, Patient, Disease, Volunteering, Pharmaceutical industry, Novartis, Facebook

LOS ANGELES, March 24, 2022 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer, has announced the latest updates to its innovative adaptive clinical trial, Precision PromiseSM, including the addition of an investigational treatment from global healthcare company, Novartis, as well as the opening of five additional sites across the country.

Key Points: 
  • Investigational Treatment From Novartis To Be Activated At Precision PromiseSM Clinical Trial Sites Across the Country, Including Five Additional Premier Cancer Institutions
    LOS ANGELES, March 24, 2022 /PRNewswire/ --The Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer, has announced the latest updates to its innovative adaptive clinical trial, Precision PromiseSM, including the addition of an investigational treatment from global healthcare company, Novartis, as well as the opening of five additional sites across the country.
  • Pancreatic cancer is the world's toughest cancer with an overall five-year survival rate of just 11 percent.
  • In addition to bringing Novartis' investigational treatment into the study, PanCAN has announced the addition of five new sites to the already fifteen active sites where pancreatic cancer patients will be able to access the trial.
  • The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients.

Mayo Clinic Collaborates With Personalis Inc. to Expand Cancer Genomic Testing

Retrieved on: 
Tuesday, October 12, 2021
Oncology, Health, Hospitals, Genetics, Pharmaceutical, Biotechnology, Mouse Models of Human Cancer database, Twitter, Efficiency, Health, Individualized medicine, College of American Pathologists, College, Genomics, Department, COVID-19, Clinical Laboratory Improvement Amendments, Culture, Growth, Cancer, Education, Genome, Liu v. Securities and Exchange Commission, Mayo Clinic Cancer Center, PSNL, Mayo Clinic, Pathology, Medicine, Immune system, Mayo, Forecasting, Medical laboratory, National, Veteran, Leadership, Chief Justice of Hungary, U.S. Securities and Exchange Commission, Patient, Research, Coronavirus, National Cancer Institute, Risk, Nasdaq, Center, Veterans' affairs, Pharmaceutical industry, Mayo Clinic, Mayo Clinic Cancer Center, Personalis Inc., MAYO CLINIC, MAYO CLINIC CANCER CENTER, PERSONALIS INC.

Mayo Clinic Cancer Center , Mayo Clinic's Department of Laboratory Medicine and Pathology , and Mayo Clinic's Center for Individualized Medicine are collaborating with Personalis Inc. (Nasdaq: PSNL), a cancer genomics company whose clinical-grade, comprehensive cancer genomic test includes sequencing the entire coding genome through whole-exome and transcriptome sequencing.

Key Points: 
  • Mayo Clinic Cancer Center , Mayo Clinic's Department of Laboratory Medicine and Pathology , and Mayo Clinic's Center for Individualized Medicine are collaborating with Personalis Inc. (Nasdaq: PSNL), a cancer genomics company whose clinical-grade, comprehensive cancer genomic test includes sequencing the entire coding genome through whole-exome and transcriptome sequencing.
  • , executive director of Mayo Clinic Cancer Programs and director of Mayo Clinic Cancer Center.
  • "We are honored to work with Mayo Clinic to increase access to advanced cancer testing," says Richard Chen, M.D., chief medical officer of Personalis.
  • Designated as a comprehensive cancer center by the National Cancer Institute , Mayo Clinic Cancer Center is defining new boundaries in possibility, focusing on patient-centered care, developing novel treatments, training future generations of cancer experts, and bringing cancer research to communities.

Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO

Retrieved on: 
Friday, May 29, 2020
NCI-designated Cancer Center, KRAS, Mayo Clinic Cancer Center, USC Norris Comprehensive Cancer Center, Health

"Being able to effectively treat patients with KRAS-mutated mCRC has been a challenge and their prognosis is poor.

Key Points: 
  • "Being able to effectively treat patients with KRAS-mutated mCRC has been a challenge and their prognosis is poor.
  • Onvansertib is showing great potential as a new second-line treatment option, in combination with standard-of-care, for these patients."
  • "Our trial is achieving critical milestones and gaining momentum," said Dr. Mark Erlander, Chief Executive Officer of Cardiff Oncology.
  • The trial is being conducted at two prestigious cancer centers: USC Norris Comprehensive Cancer Center and the Mayo Clinic Cancer Center.